Hospital
Lexington Regional Health Center
Lexington Regional Health Center was paid $4.22M by Medicaid between Jan 2018 and Nov 2024, across 106 billing codes. Its largest line is 99284, emergency room visit (serious) — 16% of everything it billed.
33Billing provider infoLEXINGTON REGIONAL HEALTH CENTER
LEXINGTON, NE 68850
LEXINGTON, NE 68850
33aNPI1467417352assigned 04/20/2006
33bProvider typeCritical Access Hospital
28Total paid$4.22M
24GClaims75,325
24DCodes billed106
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Critical Access Hospital providers in Nebraska
Rank by total paid#2 of 53
Median peer was paid$593K
This provider vs. median7.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 7,442 | $283K | |
| 2019 | 11,099 | $622K | |
| 2020 | 9,310 | $612K | |
| 2021 | 24,499 | $1.25M | |
| 2022 | 16,855 | $1.05M | |
| 2023 | 5,278 | $335K | |
| 2024incomplete | 842 | $67K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 16% | 2,238 | 1,706 | $680K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 13% | 2,841 | 2,272 | $549K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 7.1% | 8,739 | 6,832 | $299K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 6.4% | 4,716 | 1,167 | $268K |
| 80053 | Comprehensive metabolic panel | 6.2% | 5,153 | 3,861 | $263K |
| G0378 | Hospital observation service, per hour | 5.1% | 942 | 580 | $216K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.6% | 573 | 441 | $195K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2.4% | 4,314 | 3,154 | $103K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 2.1% | 485 | 476 | $89K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.0% | 589 | 476 | $83K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 1.8% | 2,644 | 1,922 | $76K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.7% | 709 | 533 | $73K |
94 more codes
| 36415 | Collection of venous blood by venipuncture | 1.6% | 6,781 | $70K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.6% | 1,445 | $69K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.6% | 651 | $67K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.4% | 4,110 | $57K |
| 87400 | 1.3% | 700 | $54K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.2% | 810 | $49K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.1% | 810 | $48K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | 1.1% | 139 | $45K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.0% | 806 | $43K |
| 97161 | <1% | 593 | $37K | |
| J3490 | Unclassified drugs | <1% | 3,043 | $35K |
| 59025 | Fetal non-stress test | <1% | 213 | $35K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,186 | $31K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 733 | $31K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,254 | $30K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 909 | $28K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 479 | $28K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 230 | $26K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 163 | $24K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 364 | $24K |
| 81001 | <1% | 1,567 | $23K | |
| 87631 | <1% | 141 | $22K | |
| 71045 | Radiologic examination, chest; single view | <1% | 243 | $22K |
| 87081 | <1% | 599 | $22K | |
| 81025 | <1% | 822 | $21K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 130 | $21K |
| 86141 | <1% | 688 | $21K | |
| 87088 | <1% | 477 | $19K | |
| 85027 | <1% | 657 | $18K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 395 | $18K |
| 80305 | <1% | 461 | $17K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 647 | $17K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 426 | $16K |
| 87210 | <1% | 662 | $15K | |
| 80061 | Lipid panel | <1% | 742 | $15K |
| 84484 | <1% | 304 | $14K | |
| 87420 | <1% | 216 | $14K | |
| 81003 | <1% | 805 | $11K | |
| 81002 | <1% | 732 | $11K | |
| 84702 | <1% | 280 | $9K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 69 | $9K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 193 | $8K |
| 85610 | <1% | 670 | $8K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 40 | $7K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 242 | $7K |
| 83690 | <1% | 330 | $7K | |
| 76801 | <1% | 28 | $7K | |
| J2704 | Injection, propofol, 10 mg | <1% | 170 | $6K |
| 73630 | <1% | 34 | $6K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 31 | $6K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 183 | $6K |
| 85730 | <1% | 198 | $5K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 92 | $5K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 159 | $4K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 246 | $4K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 143 | $4K |
| 80055 | <1% | 28 | $4K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 135 | $3K |
| 85007 | <1% | 121 | $3K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 319 | $3K |
| 88142 | <1% | 87 | $2K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 15 | $2K |
| 82950 | <1% | 96 | $2K | |
| 87077 | <1% | 86 | $2K | |
| 85379 | <1% | 71 | $2K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 27 | $2K |
| 87186 | <1% | 65 | $2K | |
| 84703 | <1% | 65 | $2K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 74 | $2K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 13 | $2K |
| 86780 | <1% | 54 | $2K | |
| 86901 | <1% | 97 | $1K | |
| 82570 | <1% | 42 | $1K | |
| 99201 | <1% | 93 | $1K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 63 | $1K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 18 | $942.80 |
| 83880 | <1% | 14 | $936.04 | |
| 84145 | <1% | 21 | $875.15 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 32 | $832.06 |
| 86900 | <1% | 33 | $749.38 | |
| 83605 | <1% | 70 | $737.07 | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 14 | $733.02 |
| 86850 | <1% | 18 | $705.83 | |
| 84439 | <1% | 26 | $671.00 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 14 | $543.51 |
| 87340 | <1% | 12 | $504.17 | |
| 82150 | <1% | 13 | $481.64 | |
| 86140 | <1% | 12 | $352.80 | |
| 86762 | <1% | 12 | $345.07 | |
| A9270 | Non-covered item or service | <1% | 226 | $340.93 |
| 83735 | <1% | 14 | $284.80 | |
| 85018 | <1% | 15 | $186.11 | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 12 | $172.80 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDOUGLAS, JASON (ADMINISTRATOR & CEO)
| Provider | Location | Paid |
|---|---|---|
| Peace of Mind Home Care, LLC | Saint Joseph, MO | $39.81M |
| Memorial Medical Center INC | Ashland, WI | $22.57M |
| Lexington Regional Health Center | Lexington, NE | $3.17M |
| Lexington Regional Health Center | Lexington, NE | $459K |
| Lexington Regional Health Center | Lexington, NE | $293K |
| Lexington Regional Health Center | Lexington, NE | $1K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.